Trial reportBritish journal of cancer1994
S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.
Trial report in British journal of cancer, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 60 citations in OpenAlex.
- Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.Journal of clinical pathology · 2005Trial
- Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer.British journal of cancer · 2005Trial
- Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.British journal of cancer · 1996Trial
- High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.Breast cancer research and treatment · 2017Article
- Multiparameter DNA content analysis identifies distinct groups in primary breast cancer.British journal of cancer · 2013Article
- Article
- Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.British journal of cancer · 2000Article
- A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.British journal of cancer · 1999Article
- [p53 status in breast carcinomas and the effect of adjuvant radio- and chemotherapies].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 1997Article
- p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group.British journal of cancer · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer chemotherapy interacts with cell proliferation, but data on the relationship between cancer cell replication and the effect of adjuvant chemotherapy are scarce. We have investigated the S-phase fractions of the primary tumour from premenopausal breast cancer patients who participated in a randomised trial comparing 12 cycles of polychemotherapy (CMF) with post-operative radiotherapy. DNA flow cytometry was performed on frozen tissues from 208 primary breast carcinomas, of which the S-phase fraction was estimated in 176 cases. There was a significantly higher benefit from CMF among patients with a high S-phase fraction (P = 0.0033). The relative risk of distant recurrence or death in the chemotherapy group as compared with the radiotherapy group was 0.19 for patients whose tumours had an S-phase fraction of 10% or over (95% CI 0.07-0.51) and 1.55 (0.88-2.73) for patients whose tumours showed lower S-phase levels. The interaction was still significant in multivariate analysis (P = 0.0057), including lymph node metastases, tumour size and oestrogen receptor content. We conclude that the benefit from adjuvant chemotherapy compared with radiotherapy is largely confined to patients with highly proliferative tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.